Safety Study of an Immune Response Modifier in Patients With Refractory Solid Organ Tumors

NCT00095160 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

42

Enrollment

OTHER

Sponsor class

Conditions

Neoplasms

Interventions

DRUG: 852A

Sponsor

Masonic Cancer Center, University of Minnesota

Collaborators

[object Object]